Board of Directors

Krisztina Zsebo, Ph.D., VasoRx CEO, Director, and Co-founder

Dr. Zsebo is a biopharmaceutical veteran with 35 years of experience in the Biotechnology industry and has been involved in numerous successful ventures.   She was CEO & President of Celladon Corporation, for 11 years and took the company public. She was also an Entrepreneur in Residence at Enterprise Partners Venture Capital. Prior to joining Enterprise, she was CEO & President of Remedyne Corporation. Before coming to Remedyne she was Executive Vice President of Connetics Corporation.  Dr. Zsebo also headed the Biopharmaceutical and Implant Division of ALZA Corporation, where she was responsible for the division which developed and filed the NDA for Viadur®, an implantable drug/device for prostate cancer patients. At Cell Genesys, where she was Executive Vice President of Research and Product Development, she managed the Xenotech division where Xenomouse was developed. It was spun off to become Abgenix, one of the most successful biotech companies.  Earlier in her career, Kris spent eight years at Amgen in research and product development where she worked on the discovery of NEUPOGEN®, as well as Stem Cell Factor, and various aspects of EPOGEN® development.
Dr. Zsebo received a B.S. in Biochemistry from the University of Maryland, a M.S. in Biochemistry and Biophysics from Oregon State University and a PhD in Comparative Biochemistry and Molecular Biology from the University of California, Berkeley. 

Jordan Green, Ph.D., John Hopkins, VasoRx Director

Dr. Green is a Professor of Biomedical Engineering, Ophthalmology, Oncology, Neurosurgery, Chemical & Biomolecular Engineering, and Materials Science & Engineering, at the Johns Hopkins University School of Medicine. He is an associate researcher of the Institute for NanoBioTechnology and co-founder and associate director of the Translational Tissue Engineering Center at JHU. Dr. Green received his B.S. in biomedical engineering and in chemical engineering from Carnegie Mellon University in 2003 and completed his Ph.D. in biological engineering from the Massachusetts Institute of Technology in 2007. Dr. Green is also a Fellow of the American Institute for Medical and Biological Engineering. He has received numerous awards including the American Institute of Chemical Engineers Allan Colburn Award, the Biomedical Engineering Society Rita Schaffer Award, the American Society for Engineering Education Curtis W. McGraw Research Award, the Presidential Early Career Award for Scientists and Engineers, and is a National Academy of Medicine Emerging Leader in Health & Medicine.

Anthony Ware, M.D., VasoRx Director

Dr. Ware served as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he was responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas. His sixteen year tenure at Eli Lilly has included the clinical development, regulatory approval and launch of numerous novel therapeutics, including Taltz®, Olumiant®, Cymbalta®, Cialis®, Effient® and Trulicity®. Prior to Eli Lilly, Dr. Ware served as Professor of Medicine and Molecular Pharmacology at Albert Einstein College of Medicine in New York, where he was also Chief of Cardiology at Montefiore Medical Center. Before then, Dr. Ware was on the faculty of Harvard Medical School and also served as a senior physician and Director of the Coronary Care Unit at Beth Israel Hospital. Dr. Ware currently serves as a member of the board of directors of AnaptysBio a NASDAQ-listed biotech company. Dr. Ware received a Bachelor of Science degree from Washburn University, a Medical Degree from the University of Kansas, has served in internships at the University of Texas at Houston and Baylor College of Medicine, and is board certified both in internal medicine and cardiovascular